Immunovant (Nasdaq: IMVT) posts Q1 2026 loss and details IMVT-1402 milestones
Rhea-AI Filing Summary
Immunovant, Inc. reported corporate updates and financial results for its fiscal first quarter ended June 30, 2026, centered on the development of IMVT-1402 across six autoimmune indications, including Graves’ disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sjögren’s disease and cutaneous lupus erythematosus.
As of June 30, 2026, cash and cash equivalents were $797.8 million, which the company states provides runway to the potential commercial launch of IMVT-1402 in Graves’ disease based on its current operating plan. For the quarter, R&D expenses were $142.6 million, up from $101.2 million a year earlier, mainly from IMVT-1402 clinical and manufacturing activities, while G&A expenses declined to $17.7 million from $26.0 million. Net loss was $153.2 million, or $0.75 per share, versus $120.6 million, or $0.71 per share, in the prior-year quarter. Non-GAAP measures exclude $13.8 million of non-cash stock-based compensation. The company highlighted upcoming IMVT-1402 milestones, including D2T RA and CLE data in the second half of 2026, GD and MG topline data in 2027, and CIDP and Sjögren’s data in 2028.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash and cash equivalents: $797.8 million
R&D expenses Q1 2026: $142.6 million
R&D expenses Q1 2025: $101.2 million
+5 more
8 metrics
Cash and cash equivalents
$797.8 million
As of June 30, 2026 cash and cash equivalents balance
R&D expenses Q1 2026
$142.6 million
Research and development expenses for three months ended June 30, 2026
R&D expenses Q1 2025
$101.2 million
Research and development expenses for three months ended June 30, 2025
G&A expenses Q1 2026
$17.7 million
General and administrative expenses for three months ended June 30, 2026
Net loss Q1 2026
$153.2 million; $(0.75) per share
Net loss and basic/diluted loss per share for three months ended June 30, 2026
Common shares outstanding
206,264,878 shares
Common stock issued and outstanding as of June 30, 2026
Total assets
$852,490 (thousands)
Total assets on balance sheet as of June 30, 2026, amounts stated in thousands
Total stockholders’ equity
$735,388 (thousands)
Total stockholders’ equity as of June 30, 2026, amounts stated in thousands
Key Terms
anti-FcRn technology, potentially registrational, proof-of-concept trial, Non-GAAP financial measures, +1 more
5 terms
anti-FcRn technology medical
"As a trailblazer in anti-FcRn technology, the Company is developing innovative therapies"
A class of drug approaches that block the neonatal Fc receptor (FcRn), a protein that acts like a recycling center for antibodies in the body. By inhibiting FcRn, these therapies speed the removal of circulating IgG antibodies, which can reduce levels of disease-causing antibodies in autoimmune conditions. Investors watch anti-FcRn technology because trial results, regulatory decisions, partnerships, and potential market size for autoimmune and antibody-driven diseases affect a company’s clinical and commercial prospects.
potentially registrational regulatory
"topline data are anticipated for the potentially registrational trials evaluating IMVT-1402"
A trial or study described as "potentially registrational" is one that is designed to produce the kind of data regulators would need to decide whether to approve a drug or medical product, though it is not a guarantee of approval. Think of it as a key audition or final exam: if the results meet regulators’ standards, they can form the basis for marketing authorization. Investors care because positive results can unlock product sales and valuation gains, while negative results can sharply reduce expected future revenue and increase uncertainty.
proof-of-concept trial medical
"report topline data from the proof-of-concept trial of IMVT-1402 in CLE"
A proof-of-concept trial is an early clinical study that tests whether a new drug or medical treatment produces the intended effect in people; think of it as a prototype demo that checks if the idea actually works in real patients. For investors it matters because positive results lower scientific and commercial risk, increase the likelihood of further development and regulatory approval, and often trigger share-price moves or new financing, while negative results can sharply reduce a project’s value.
Non-GAAP financial measures financial
"Immunovant reports certain financial results that differ as Non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
cash runway financial
"cash and cash equivalents totaled $797.8 million, providing runway to the potential launch"
Cash runway is the amount of time a company can continue operating using its available cash before needing additional funding or generating enough revenue. It’s like a countdown showing how long a business can keep running with its current funds. Knowing the cash runway helps investors assess the company's financial health and whether it has enough resources to reach its goals or needs to find more support soon.
Earnings Snapshot
Net loss (GAAP): $153.2 million; $(0.75) per share · Guidance included
Three months ended June 30, 2026
Net loss (GAAP)
$153.2 million; $(0.75) per share
vs $120.6 million; $(0.71) per share for the prior-year quarter
R&D expenses (GAAP)
$142.6 million
vs $101.2 million for the prior-year quarter
G&A expenses (GAAP)
$17.7 million
vs $26.0 million for the prior-year quarter
Cash and cash equivalents
$797.8 million
as of June 30, 2026; discussed as providing runway to a potential IMVT-1402 launch
Guidance
Management states that its cash and cash equivalents provide runway to the potential commercial launch of IMVT-1402 in Graves’ disease based on the current operating plan, and outlines topline data milestones from 2026 through 2028 across multiple indications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Immunovant (IMVT)’s key financial results for the quarter ended June 30, 2026?
Immunovant reported a net loss of $153.2 million, or $0.75 per share, for the quarter ended June 30, 2026. R&D expenses were $142.6 million and G&A expenses were $17.7 million, reflecting significant IMVT-1402 development spending and lower overhead costs.
How much cash does Immunovant (IMVT) have, and what runway does management describe?
As of June 30, 2026, Immunovant held $797.8 million in cash and cash equivalents. The company states this balance provides runway to the potential commercial launch of IMVT-1402 in Graves’ disease, based on its current operating plan and anticipated development expenditures.
What are the upcoming clinical milestones for Immunovant (IMVT)’s IMVT-1402 program?
Immunovant plans further updates on its potentially registrational D2T RA program and CLE proof-of-concept topline data in the second half of 2026. Topline data in Graves’ disease and myasthenia gravis are anticipated in 2027, followed by CIDP and Sjögren’s disease in 2028.
How did Immunovant (IMVT)’s R&D and G&A expenses compare with the prior-year quarter?
For the quarter ended June 30, 2026, R&D expenses were $142.6 million, compared with $101.2 million a year earlier, mainly from IMVT-1402 activities. G&A expenses decreased to $17.7 million from $26.0 million, driven by lower personnel, professional fees, market research and IT costs.
What non-GAAP financial measures did Immunovant (IMVT) report for the quarter?
Immunovant reported non-GAAP R&D expenses of $135.4 million, non-GAAP G&A expenses of $11.2 million, and a non-GAAP net loss of $139.4 million. These measures primarily exclude $13.8 million of non-cash stock-based compensation from GAAP results to aid management’s operational analysis.
What is Immunovant (IMVT)’s business focus and relationship with Roivant?
Immunovant is a clinical-stage immunology company developing targeted therapies for autoimmune diseases, led by its anti-FcRn antibody IMVT-1402. It is a majority-owned subsidiary of Roivant and positions itself as a trailblazer in anti-FcRn technology for complex autoimmune conditions.